Login / Signup

The Beta2-adrenergic agonist salbutamol synergizes with paclitaxel on cell proliferation and tumor growth in triple negative breast cancer models.

Martina JabloñskiMaría Sol RodríguezEzequiel Mariano RiveroCarlos David BruqueSilvia VanzulliAriana BruzzoneCecilia Pérez PiñeroIsabel Alicia Lüthy
Published in: Cancer chemotherapy and pharmacology (2023)
While the effect of salbutamol was mainly on cell proliferation, suboptimal concentrations of paclitaxel provoked a very important enhancement of apoptosis. The latter enhanced transporter proteins as MDR1, whose expression were diminished by salbutamol. The expression of ADRB2 should be assessed in the biopsy or tumor to eventually select patients that could benefit from salbutamol repurposing.
Keyphrases